LPCAT1 and hepatocellular carcinoma: In addition, genetic interventions targeting PPM1B/USP10-Y-box binding protein 1 (YBX1) axis or lysophosphatidylcholine acyltransferase 1 (LPCAT1) enhance PANoptosis-related protein activation, effectively suppressing gastric and hepatocellular carcinoma progression [16, 64].